

# Ricard Cervera i Segura

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/519398/ricard-cervera-i-segura-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291  
papers

19,796  
citations

67  
h-index

136  
g-index

341  
ext. papers

24,226  
ext. citations

6.2  
avg, IF

6.49  
L-index

#	Paper	IF	Citations
291	Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 1019-27		1324
290	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3918-30		944
289	Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. <i>Medicine (United States)</i> , <b>2003</b> , 82, 299-308	1.8	863
288	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1771-82	2.4	692
287	Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 2121-31		649
286	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 736-745	2.4	628
285	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
284	Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. <i>American Journal of Medicine</i> , <b>1994</b> , 96, 3-9	2.4	411
283	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 958-67	2.4	388
282	Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. <i>Medicine (United States)</i> , <b>1998</b> , 77, 195-207	1.8	374
281	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, 209	5.7	373
280	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 17-23	2.4	360
279	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
278	Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2083-9	2.4	335
277	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1296-1304	2.4	312
276	Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , <b>1999</b> , 78, 167-75	1.8	293
275	Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. <i>Medicine (United States)</i> , <b>2001</b> , 80, 355-77	1.8	281

274	Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1343-9	2.4	261
273	Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 3934-40		255
272	Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". <i>Journal of Autoimmunity</i> , <b>2009</b> , 32, 240-5	15.5	245
271	Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2568-76		229
270	Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. <i>Medicine (United States)</i> , <b>1997</b> , 76, 203-12	1.8	194
269	Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. <i>Annals of the Rheumatic Diseases</i> , <b>1998</b> , 57, 456-9	2.4	194
268	Diagnosis and classification of the antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , <b>2014</b> , 48-49, 20-5	15.5	176
267	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175
266	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , <b>2017</b> , 8, 16021	17.4	171
265	Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 1085-90	13.6	158
264	Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. <i>Pediatrics</i> , <b>2008</b> , 122, e1100-7	7.4	151
263	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 1120-1124	13.6	147
262	Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1305-13	9.5	146
261	Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 37-43	2.4	136
260	Etiopathogenesis of Behçet's disease. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 241-5	13.6	130
259	Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. <i>Medicine (United States)</i> , <b>2003</b> , 82, 106-18	1.8	129
258	Antiphospholipid syndrome. <i>Thrombosis Research</i> , <b>2017</b> , 151 Suppl 1, S43-S47	8.2	128
257	Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2143-53		119

256	High prevalence of significant heart valve lesions in patients with the 'primary' antiphospholipid syndrome. <i>Lupus</i> , <b>1991</b> , 1, 43-7	2.6	116
255	Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. <i>Seminars in Arthritis and Rheumatism</i> , <b>2004</b> , 33, 217-30	5.3	114
254	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 281-91	13.6	112
253	Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. <i>Rheumatology</i> , <b>2005</b> , 44, 756-61	3.9	110
252	Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. <i>Autoimmunity Reviews</i> , <b>2010</b> , 10, 74-9	13.6	106
251	Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 35, 322-32	5.3	106
250	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 526-31	2.4	104
249	Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 180-6	13.6	99
248	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 838-44	2.4	98
247	Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 1420-7		93
246	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2017</b> , 76, 10-20	15.5	91
245	Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 153-9	13.6	87
244	The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , <b>2018</b> , 92, 1-11	15.5	87
243	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000123	4.6	86
242	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 387-95	13.6	84
241	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 914-921	13.6	84
240	'Primary', 'secondary' and other variants of the antiphospholipid syndrome. <i>Lupus</i> , <b>1994</b> , 3, 293-8	2.6	83
239	Current treatment of antiphospholipid syndrome: lights and shadows. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 586-96	8.1	78

238	Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 2801-6		78
237	Systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2010</b> , 24, 841-55	5.3	77
236	Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. <i>Medicine (United States)</i> , <b>2001</b> , 80, 345-54	1.8	77
235	Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2010</b> , 39, 246-56	5.3	76
234	Bidirectional effects on autoimmunity and reproduction. <i>Human Reproduction Update</i> , <b>2008</b> , 14, 359-66	15.8	73
233	Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 1166-70	13.6	72
232	Adalimumab for the treatment of Behçet's disease: experience in 19 patients. <i>Rheumatology</i> , <b>2012</b> , 51, 1825-31	3.9	72
231	Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 70-6	4.9	72
230	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 740-6	2.4	72
229	The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 483-493	3.9	72
228	Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 72-5	13.6	69
227	Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry". <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 157-62	13.6	68
226	Hepatitis C virus infection in 'primary' Sjögren's syndrome: prevalence and clinical significance in a series of 90 patients. <i>Annals of the Rheumatic Diseases</i> , <b>1997</b> , 56, 173-5	2.4	64
225	Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 1009-16	11.6	63
224	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 93-106	13.6	63
223	Microvascular and microangiopathic antiphospholipid-associated syndromes ("MAPS"): semantic or antisemantic?. <i>Autoimmunity Reviews</i> , <b>2008</b> , 7, 164-7	13.6	62
222	Antiphospholipid syndrome: pathogenic mechanisms. <i>Autoimmunity Reviews</i> , <b>2003</b> , 2, 86-93	13.6	62
221	The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 2349-58		61

220	Management of refractory cases of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 664-8	13.6	59
219	Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 333-8	5.3	59
218	Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. <i>American Journal of Reproductive Immunology</i> , <b>2005</b> , 53, 182-8	3.8	59
217	Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 460-7		58
216	Prevalence of hepatitis C serum antibody in autoimmune diseases. <i>Journal of Autoimmunity</i> , <b>2009</b> , 32, 261-6	15.5	56
215	The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. <i>International Immunology</i> , <b>2007</b> , 19, 857-65	4.9	54
214	Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 287-96	5.3	54
213	Patterns of systemic lupus erythematosus expression in Europe. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 621-9	13.6	53
212	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 679-84	13.6	53
211	Relapsing catastrophic antiphospholipid syndrome: report of three cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2008</b> , 37, 366-72	5.3	53
210	Annual direct medical cost of active systemic lupus erythematosus in five European countries. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 154-60	2.4	52
209	Unusual manifestations of the antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2003</b> , 25, 61-78	12.3	52
208	Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). <i>Current Rheumatology Reports</i> , <b>2018</b> , 20, 62	4.9	51
207	Factors influencing polyautoimmunity in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 229-32	13.6	51
206	Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 290-4	5.3	50
205	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 9-15	13.6	49
204	Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 703-708	13.6	49
203	Diagnosis and classification of Susac syndrome. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 347-50	13.6	49

202	The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 204-9	13.6	49
201	The multiple autoimmune syndromes. A clue for the autoimmune tautology. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2012</b> , 43, 256-64	12.3	48
200	Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 296-300	8.1	48
199	Risk factors of vertebral fractures in women with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , <b>2009</b> , 28, 579-85	3.9	48
198	Moving towards a molecular taxonomy of autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 75-93	8.1	47
197	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2071-4	2.4	47
196	Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R41	5.7	45
195	Epidemiology and management of refractory lupus nephritis. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 655-63	13.6	44
194	Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 61-6	2.4	44
193	Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 48-53	13.6	44
192	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 1153-1168	13.6	43
191	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000793	3.9	42
190	Does seronegative antiphospholipid syndrome really exist?. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 581-4	13.6	41
189	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , <b>2018</b> , 57, 1264-1270	3.9	40
188	Catastrophic APS in the context of other thrombotic microangiopathies. <i>Current Rheumatology Reports</i> , <b>2015</b> , 17, 482	4.9	40
187	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 406-414	13.6	39
186	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. <i>Immunobiology</i> , <b>2005</b> , 210, 735-41	3.4	39
185	Coronary and valvular syndromes and antiphospholipid antibodies. <i>Thrombosis Research</i> , <b>2004</b> , 114, 501-8.2	8.2	39

184	Catastrophic Antiphospholipid Syndrome. <i>Journal of Clinical Rheumatology</i> , <b>2002</b> , 8, 157-165	1.1	39
183	Pregnancy outcome in systemic lupus erythematosus: good news for the new millennium. <i>Autoimmunity Reviews</i> , <b>2002</b> , 1, 354-9	13.6	39
182	Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. <i>Immunologic Research</i> , <b>2013</b> , 56, 358-61	4.3	36
181	Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2009</b> , 36, 80-4	12.3	36
180	Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2010</b> , 37, 154-8	3	34
179	Clinical and epidemiological aspects in the antiphospholipid syndrome. <i>Immunobiology</i> , <b>2003</b> , 207, 5-11	3.4	34
178	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 1924-30	4.3	33
177	Lessons from the "Euro-Phospholipid" project. <i>Autoimmunity Reviews</i> , <b>2008</b> , 7, 174-8	13.6	32
176	Catastrophic antiphospholipid syndrome: task force report summary. <i>Lupus</i> , <b>2014</b> , 23, 1283-5	2.6	31
175	Amputation of digits or limbs in patients with antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2008</b> , 38, 124-31	5.3	30
174	Catastrophic antiphospholipid syndrome: The current management approach. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 239-249	5.3	30
173	Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 750-755	13.6	29
172	Solid cancer, antiphospholipid antibodies, and venous thromboembolism. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 222-7	13.6	29
171	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 721-726	4.1	29
170	Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 586-93	13.6	28
169	Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: a systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 607-16	13.6	27
168	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1073-1085	9.5	27
167	Vitamin D and Sjögren syndrome. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 587-593	13.6	26



166	The role of infectious diseases in the catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 1066-71	13.6	26
165	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , <b>2020</b> , 59, 1306-1314	3.9	26
164	Systemic lupus erythematosus and hypertension. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102371	13.6	25
163	Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , <b>2009</b> , 28, 65-70	3.9	25
162	Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 81-4	13.6	25
161	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 1074-1082	6.1	24
160	Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. <i>Immunologic Research</i> , <b>2013</b> , 56, 287-92	4.3	24
159	Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 42, 417-23	5.3	24
158	Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 68-71	13.6	24
157	Catastrophic antiphospholipid syndrome: an update. <i>Panminerva Medica</i> , <b>2017</b> , 59, 254-268	2	23
156	Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. <i>Clinics in Laboratory Medicine</i> , <b>2013</b> , 33, 391-400	2.1	22
155	Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196113	3.7	21
154	Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2012</b> , 43, 265-74	12.3	21
153	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000785	5.9	21
152	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 374-382	6.1	20
151	Renal involvement in antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , <b>2014</b> , 16, 397	4.9	20
150	Val247Leu $\beta$ -glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 705-12	13.6	20
149	Susac's syndrome: an update. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 548-52	13.6	20

148	Autoimmunity and recurrent pregnancy losses. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2010</b> , 39, 148-153	2.0	20
147	Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study. <i>Revista Clinica Espanola</i> , <b>2013</b> , 213, 127-37	0.7	19
146	Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 515-29	6.5	19
145	European Working Party on Systemic Lupus Erythematosus: a 15-year report. <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 549-53	13.6	19
144	Antiphospholipid syndrome. <i>Arthritis Research and Therapy</i> , <b>2008</b> , 10, 230	5.7	18
143	Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 448-56	6.5	18
142	Catastrophic antiphospholipid syndrome. <i>Rheumatic Disease Clinics of North America</i> , <b>2006</b> , 32, 575-90	2.4	18
141	Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1582-1592	2.3	17
140	Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 1839-1862	3.5	17
139	The epidemiology and significance of autoimmune diseases in health care. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2001</b> , 235, 27-30	2	17
138	Novelties in the field of autoimmunity - 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 1175-1184	13.6	16
137	Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Atherosclerosis</i> , <b>2020</b> , 297, 55-63	3.1	16
136	Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre. <i>BioMed Research International</i> , <b>2014</b> , 2014, 746192	3	16
135	Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 85-8	13.6	16
134	Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 3283-9		16
133	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report <b>2017</b> , 317-338		16
132	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1820-1826	4.7	16
131	"Non-criteria" antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102689	13.6	15

130	Do we still need renal biopsy in lupus nephritis?. <i>Reumatologia</i> , <b>2016</b> , 54, 61-6	1.7	15
129	Automated Detection of Lupus White Matter Lesions in MRI. <i>Frontiers in Neuroinformatics</i> , <b>2016</b> , 10, 33	3.9	15
128	Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 184-191	13.6	15
127	Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. <i>Journal of Clinical Rheumatology</i> , <b>2002</b> , 8, 157-65	1.1	15
126	The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 929-935	2.2	15
125	Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1895-6	4.1	14
124	Basophils, IgE, and autoantibody-mediated kidney disease. <i>Journal of Immunology</i> , <b>2011</b> , 186, 6083-90	5.3	14
123	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102738	13.6	14
122	Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis. <i>American Journal of Nephrology</i> , <b>2016</b> , 44, 439-446	4.6	13
121	Morbidity and mortality in the antiphospholipid syndrome. <i>Current Opinion in Pulmonary Medicine</i> , <b>2009</b> , 15, 413-7	3	13
120	Antiphospholipid syndrome. <i>Journal of Investigative Dermatology</i> , <b>1993</b> , 100, 21S-27S	4.3	13
119	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	13
118	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1490-1501	4.7	13
117	Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 926-32	2.2	13
116	Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2015</b> , 7, 26-30	3.8	12
115	Magnetic Resonance Imaging in Neuropsychiatric Lupus. <i>F1000Research</i> , <b>2015</b> , 4, 162	3.6	12
114	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , <b>2020</b> , 961203320940776	2.6	12
113	Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1218-1226	2.4	11

112	Lack of association between serum 25-hydroxyvitamin D levels and cervical human papillomavirus infection in systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 606-12	2.6	10
111	Venous thromboembolic disease in systemic autoimmune diseases: an association to keep in mind. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 289-94	13.6	10
110	Catastrophic antiphospholipid syndrome - 20 years later. <i>Current Rheumatology Reviews</i> , <b>2013</b> , 9, 73-80	1.6	10
109	16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. <i>Lupus</i> , <b>2020</b> , 29, 1594-1600	2.6	10
108	Lessons from the "Euro-Lupus Cohort". <i>Annales De Médecine Interne</i> , <b>2002</b> , 153, 530-6		10
107	Magnetic Resonance Imaging in Neuropsychiatric Lupus. <i>F1000Research</i> , <b>2015</b> , 4, 162	3.6	9
106	Treat-to-target in systemic lupus erythematosus: Where are we?. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 74, 29-34	3.9	9
105	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , <b>2021</b> , 117, 102580	15.5	9
104	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , <b>2020</b> , 29, 1050-1059	2.6	8
103	Association between allelic variants of the human glucocorticoid receptor gene and autoimmune diseases: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 449-456	13.6	8
102	The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , <b>2018</b> , 169, 128-134	8.2	8
101	Facts and challenges for the autoimmunologist. Lessons from the second Colombian autoimmune symposium. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 249-51	13.6	8
100	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 1119-1124	13.6	8
99	Systemic lupus erythematosus 2014. <i>Autoimmune Diseases</i> , <b>2014</b> , 2014, 274323	2.9	8
98	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	8
97	Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 695-9	3.9	7
96	Incidence of Vertebral Fractures in Women with Systemic Lupus Erythematosus After 8 Years of Follow-Up. <i>Calcified Tissue International</i> , <b>2017</b> , 101, 291-299	3.9	7
95	Genital Mycoplasma infection among Mexican women with systemic lupus erythematosus. <i>International Journal of Gynecology and Obstetrics</i> , <b>2017</b> , 138, 17-22	4	7

94	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102406	13.6	7
93	Anti-GalNAc $\alpha$ novel anti-glycan autoantibody associated with pregnancy loss in women with antiphospholipid syndrome and in a mouse experimental model. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 420-425	15.5	7
92	Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis. <i>American Journal of Reproductive Immunology</i> , <b>2009</b> , 62, 381-9	3.8	7
91	Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the catastrophic antiphospholipid syndrome. <i>APLAR Journal of Rheumatology</i> , <b>2004</b> , 7, 254-262		7
90	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
89	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , <b>2020</b> , 6,	5.9	7
88	Carotid atherosclerosis is not associated with lower bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 25-31	2.6	6
87	Management of Reproductive Failure in the Antiphospholipid Syndrome <b>2002</b> , 375-394		6
86	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , <b>2020</b> , 59, 3690-3699	3.9	5
85	Systemic lupus erythematosus, endothelial progenitor cells and intracellular Ca signaling: A novel approach for an old disease. <i>Journal of Autoimmunity</i> , <b>2020</b> , 112, 102486	15.5	5
84	Plasma exchange in catastrophic antiphospholipid syndrome. <i>Presse Medicale</i> , <b>2019</b> , 48, 347-353	2.2	5
83	The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 1897-1905	4.8	5
82	Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 267-276	3.5	5
81	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. <i>Antibodies</i> , <b>2016</b> , 5,	7	5
80	Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2323-2330	3.9	4
79	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 2069-2080	15.4	4
78	Recambio plasmático en las enfermedades autoinmunes sistémicas. <i>Seminarios De La Fundación Española De Reumatología</i> , <b>2013</b> , 14, 43-50		4
77	Factors Associated with Mortality in Patients with Autoimmune Diseases Admitted to the Intensive Care Unit in Bogota, Colombia. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 337	8.4	4

76	Management of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , <b>2010</b> , 1, 15-22	3.7	4
75	Future Perspectives in the Diagnosis of Neuropsychiatric Lupus by Advanced Magnetic Resonance Imaging Techniques. <i>Current Rheumatology Reviews</i> , <b>2018</b> , 14, 213-218	1.6	4
74	Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1275-1284	4.1	4
73	The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 2057-2063	3.9	4
72	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , <b>2019</b> , 86, 363-368	2.9	4
71	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 541-547	4.1	4
70	Autoantibodies, elevated cytokines, and neurocognitive abnormalities in offspring of women with systemic lupus erythematosus: comparison with healthy controls. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 2529-2539	3.9	3
69	Cardiac manifestations of the antiphospholipid syndrome. <i>Coronary Artery Disease</i> , <b>1993</b> , 4, 1137-43	1.4	3
68	Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry".. <i>Autoimmunity Reviews</i> , <b>2022</b> , 21, 103055	13.6	3
67	FRI0193 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS <b>2019</b> ,		3
66	Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S67-71	2.2	3
65	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. <i>Scientific Reports</i> , <b>2020</b> , 10, 11010	4.9	2
64	Systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2017</b> , 31, 289-290	5.3	2
63	Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. <i>Clinical Investigation</i> , <b>2015</b> , 5, 561-571		2
62	Thromboembolism risk following recurrent miscarriage. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 1503-13	2.5	2
61	Current management of catastrophic antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , <b>2011</b> , 6, 297-303	1.5	2
60	The epidemiology of systemic lupus erythematosus: a review of the current data with special emphasis on the lessons from the Euro-lupus Cohort. <i>APLAR Journal of Rheumatology</i> , <b>2003</b> , 6, 150-157		2
59	Next step in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. <i>Lupus</i> , <b>2021</b> , 30, 134-140	2.6	2

58	Prolactin and Estradiol Profile in a Cohort of Colombian Women with Systemic Lupus Erythematosus. <i>Israel Medical Association Journal</i> , <b>2016</b> , 18, 537-541	0.9	2
57	History, Classification, and Subsets of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 1-16	0.3	1
56	Treatment of Catastrophic Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 243-255	0.3	1
55	Diagnosing catastrophic antiphospholipid syndrome: the necessity for clinical awareness. <i>International Journal of Clinical Rheumatology</i> , <b>2014</b> , 9, 1-3	1.5	1
54	Correction: Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 404	5.7	1
53	Ronald A. Asherson In Memoriam <i>Clinical Reviews in Allergy and Immunology</i> , <b>2009</b> , 36, 71-73	12.3	1
52	Systemic lupus erythematosus. <i>Autoimmune Diseases</i> , <b>2012</b> , 2012, 815753	2.9	1
51	Catastrophic antiphospholipid (Asherson's) syndrome. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2008</b> , 69, 384-7	0.8	1
50	Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders.. <i>Autoimmunity Reviews</i> , <b>2021</b> , 21, 103014	13.6	1
49	15th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome Report <b>2017</b> , 307-316		1
48	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases		1
47	Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 30-41	5.1	1
46	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 278	5.7	1
45	Catastrophic antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 28, 39-43	0.2	1
44	Repeat renal biopsy in lupus nephritis - unnecessary harm and risk of complications or important diagnostic tool with clinical consequences?. <i>Reumatologia</i> , <b>2016</b> , 54, 49-50	1.7	1
43	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , <b>2021</b> , 60, e181-e183	3.9	1
42	136 Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , <b>2018</b> , 57,	3.9	1
41	COVID-19 coagulopathy and antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> ,	0.2	1

40	Deletions in are a risk factor for antibody-mediated kidney disease.. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 1004715	1	1
39	Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature.. <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	1
38	Thrombotic Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 12, 87-106	0.3	0
37	The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 9	5.7	0
36	Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 754469	8.4	0
35	Targeting interferon I in SLE: a promising new perspective. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e581-e582	4.2	0
34	Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. <i>Expert Review of Hematology</i> , <b>2021</b> , 14, 457-466	2.8	0
33	Treat to target in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 28, 101-106	0.2	0
32	Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 28, 82-89	0.2	0
31	Antimalarial-induced retinal toxicity. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 28, 132-132	0.2	0
30	The impact of antimalarial agents on traditional and non-traditional subclinical atherosclerosis biomarkers in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102887	13.6	0
29	Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 91	5.7	0
28	Prognosis in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 12, 281-294	0.3	0
27	Research on biological therapies in systemic lupus erythematosus. <i>Medicina Clínica (English Edition)</i> , <b>2017</b> , 148, 67-68	0.3	0
26	Overrepresentation of Elderly Subjects in a Population-Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarte-García et al. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1768-1769	9.5	0
25	Catastrophic Antiphospholipid Syndrome <b>2019</b> , 493-500		
24	Reply to the editor. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 435-436	13.6	0
23	Le Relapsing Polychondritis Damage Index (RPDAM) : développement d'un score clinique au cours de la polychondrite atrophiante. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2020</b> , 87, 122-127	0.1	0



22	The Infectious Origin of the Anti-Phospholipid Syndrome <b>2015</b> , 681-696	
21	Pathogenic Mechanisms and Clinical Relevance of Autoantibodies <b>2014</b> , 51-57	
20	Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 480	9.5
19	Editorial paper Catastrophic antiphospholipid syndrome: 20 years of research work (1992-2012). <i>Reumatologia</i> , <b>2012</b> , 5, 363-369	1.7
18	Developing an appropriately supported CME-accredited programme in Europe. <i>Journal of European CME</i> , <b>2013</b> , 2, 37-44	0.6
17	Treatment of Antiphospholipid Syndrome <b>2011</b> , 1027-1042	
16	Therapeutic Perspectives in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , <b>2011</b> , 7, 313-321	1.6
15	Catastrophic antiphospholipid syndrome: therapeutic developments. <i>Expert Review of Clinical Immunology</i> , <b>2007</b> , 3, 277-85	5.1
14	Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry.. <i>Lupus</i> , <b>2022</b> , 9612033291070973	2.6
13	Relationship between serum lipopolysaccharide binding protein levels, disease activity, and clinical characteristics in Paraguayan patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2021</b> , 30, 2089-2094	2.6
12	The Catastrophic Antiphospholipid Syndrome. <i>Rare Diseases of the Immune System</i> , <b>2015</b> , 249-262	0.2
11	Task Force Report on Catastrophic Antiphospholipid Syndrome <b>2012</b> , 181-193	
10	Task Force Report on Non-criteria Manifestations: Cardiac Valve Disease <b>2012</b> , 223-233	
9	Immunotherapeutic agents for SLE <b>2012</b> , 2-6	
8	Belimumab in SLE <b>2012</b> , 42-54	
7	Recurrent Miscarriage and the Risk of Autoimmune Disease and Thromboembolic Disease 146-156	
6	Causes of Hospitalization in Systemic Lupus Erythematosus: A Narrative Review. <i>Current Rheumatology Reviews</i> , <b>2021</b> , 17, 29-40	1.6
5	Catastrophic antiphospholipid syndrome presenting with aortic dissection: case report and review of the literature. <i>Lupus</i> , <b>2021</b> , 30, 1005-1009	2.6

- 4 Systemic Lupus Erythematosus and Antiphospholipid Syndrome. *Rare Diseases of the Immune System*, **2016**, 183-198 0.2
- 3 ¿Sigue siendo necesaria la biopsia renal en la nefropatía lúpica?. *Revista Colombiana De Reumatología*, **2016**, 23, 69-72 0.2
- 2 Is the renal biopsy still necessary in lupus nephropathy?. *Revista Colombiana De Reumatología (English Edition)*, **2016**, 23, 69-72 0.1
- 1 Anti Ro52 antibodies: One step further, but still not there yet. *European Journal of Internal Medicine*, **2021**, 91, 31-32 3.9